Latest News and Press Releases

42% reduction in mean intraocular pressure (IOP) compared to baseline (p<0.0001)100% of patients were off all topical IOP-lowering medications at 24 months100% of treated patients achieved 20/30 or...

ALISO VIEJO, Calif., Sept. 16, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a late-stage biopharmaceutical company, today announced the appointment of Anand Sundaram as the company’s Vice President,...

  ALISO VIEJO, Calif., Aug. 19, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a privately held ophthalmic biotechnology company, today announced the appointment of Elizabeth (Liz) O’Farrell to its...

Financing supports SpyGlass Pharma’s platform through the readout of two Phase III pivotal trials ALISO VIEJO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma, a privately held ophthalmic...

All patients achieved 20/30 or better best corrected distance visual acuity (BCDVA)Significant IOP reduction at 18 months was also demonstrated with 100% of patients off all topical IOP-lowering...

Dr. Pujara brings extensive industry experience to guide late-stage development of the SpyGlass Drug Delivery Platform ALISO VIEJO, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- SpyGlass Pharma™, a...

SpyGlass prepares for End of Phase II meeting with the FDA to advance its Drug Delivery Platform into Phase III pivotal studiesInnovative platform has the potential to enable all cataract surgeons to...

Mean intraocular pressure (IOP) was reduced by 43.7% from baseline at month 18All patients remained off topical IOP-lowering medications and achieved >20% IOP reductionAll eyes achieved Visual...

  Share Mean intraocular pressure (IOP) reduction from washed-out baseline was 44.6% at Month 12; all patients had IOP reduction >20% and IOP ≤ 18 mmHg. 100% of patients remained off topical...

Margot Goodkin, M.D., Ph.D., appointed Chief Medical OfficerBilal Khan, MBA, CEO of New World Medical, appointed to the SpyGlass Board of Directors ALISO VIEJO, Calif., Dec. 05, 2023 (GLOBE...